Table 2.

Comparison of patient’s characteristics between HR (+) and HR (−) in the subgroup of patients treated with chemotherapy without OST

n(total)= 252	Hormone receptor (+) n=179 (71%)	Hormone receptor (−) n=73 (29%)	p
age (years)
≤35 n=50	34 (18.8%)	16 (22.5 %)/
>35 n=202	147 (81.2%)	55 (77.5 %)	p=0.502
Surgery
BCS n=162	118 (65.2%)	44 (62.9 %)
MRM n=88	63 (34.8 %)	26 (37.1 %)	p=0.529
LVI (−) n=167	118 (65.2 %)/	49 (69%)/
LVI (+) n= 85	63 (34.8 %)	22 (31 %)	p=0.564
Multicentricity/multifocality
None n=181	125 (69 %)/	56 (78.9 %)/
Yes n=71	56 (31 %)	15 (21.1%)	p=0.119
Axillary dissection
None n=181	64 (35.4 %)/	31 (43.7 %)/
Yes n=157	117 (64.6 %)	40 (56.3 %)	p=0.221
HER - 2
Negative n=186	138(76 %)/	48 (68 %)/
Positive n=65	43 (24 %)	23 (32 %)	p=0.188
CIA
Negative n=107	69 (38%)/	38 (53.5 %)/
Positive n=145	112 (62%)	33 (46.5 %)	p<0.026
CT
Taxane (+) n=115	73 (40 %)/	42 (59%)/
Taxane (−) n=137	108 (60 %)	29 (41 %)	p=0.010
RT
No n=26	17 (9.4 %)/	9 (12.7 %)/
Yes n=226	164 (90.6 %)	62 (87.3 %)	p=0.441
Pathological stage
1 n=68	47 (26 %)/	21 (29.6 %)/
2+3 n=184	134 (74 %)	50 (70.4 %)	p=0.561
Histological Grade
1/n=84	66 (36.5 %)/	18 (25.4 %)/
2+3 n=168	115 (63.5 %)	53 (74.6 %)	p=0.092
Lymph Node
Positive n=123	80 (44.2 %)/	43 (60.6 %)/
Negative n=129	101 (55.8 %)	28 (39.4 %)	p=0.019

OA: over ablation; CT: chemotherapy; LVI: lymphovascular invasion; RT: radiotherapy